Glycohale-F Rotacap is a combination bronchodilator containing Formoterol (12 mcg) and Glycopyrrolate (25 mcg), indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. Formoterol is a long-acting beta2-adrenergic agonist that provides sustained bronchodilation by relaxing airway smooth muscle, thereby improving airflow and reducing symptoms such as breathlessness and wheezing. Glycopyrrolate is a long-acting muscarinic antagonist that inhibits the action of acetylcholine on airway smooth muscle, leading to further bronchodilation and decreased mucus secretion. The combination of these two agents offers complementary mechanisms of action, resulting in enhanced bronchodilatory effects and improved lung function compared to monotherapy. Glycohale-F Rotacap is administered via a dry powder inhaler, ensuring targeted delivery to the lungs with rapid onset of action and prolonged duration, facilitating twice-daily dosing. It is essential for patients to use this medication regularly as prescribed to achieve optimal symptom control and reduce the frequency of exacerbations. Glycohale-F Rotacap is not intended for relief of acute bronchospasm. Common adverse effects may include dry mouth, headache, and tremors. Caution is advised in patients with cardiovascular disorders, and use should be guided by a healthcare professional.